

Cipla teams up with Roche to sell 2 cancer drugs in India

28 February 2018 | News

The pharma major will distribute Tocilizumab and Syndyma, the second brand of Roche's cancer therapy bevacizumab in India.



Mumbai based drug firm Cipla has entered into an agreement with Roche Pharma to promote and distribute the latter's cancer drugs in India.

The pharma major will distribute Tocilizumab and Syndyma, the second brand of Roche's cancer therapy bevacizumab in India.

This partnership is in line with Cipla and Roche's efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

According to Cipla, the prevalence of cancer and rheumatoid arthritis is widely spread across India, and the company intends to contribute to provide broader access to innovative medicines like tocilizumab and bevacizumab.